Arcutis Biotherapeutics, Inc. 4

Howard G. Welgus exercised 4,096 stock options and sold 4,730 shares of Arcutis Biotherapeutics, Inc. common stock on 2026-08-17 under a 10b5-1 plan.

On August 17, 2026, Howard G. Welgus of Arcutis Biotherapeutics, Inc. exercised three tranches of stock options for a total of 4,096 shares of common stock at strike prices of $6.5223, $7.51, and $8.63 per share, and simultaneously sold 4,730 shares of common stock at a weighted average price of $26.1807 per share under a pre-arranged Rule 10b5-1 trading plan adopted on March 13, 2026. The option exercises (all fully vested) added 822, 1,019, and 2,255 shares to his direct holdings, which then declined modestly due to the sale, leaving him with 36,475 shares of common stock directly owned after the transactions. The exercises represent an aggregate option exercise cost of roughly $31,800 and an intrinsic value (based on the sale price context) of roughly $80,000–$85,000, while the sale generated proceeds of approximately $124,000, suggesting a largely monetizing/covering transaction rather than a major change in his economic exposure.

Filing Facts

CIK

1787306

Ticker

ARQT

Form

4

Source Type

fda

Accession

0001628280-26-058008

Alert Tier

5